Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report

BACKGROUND: Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous thrombolytic therapy with recombinant tissue...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtani, Toshiyuki, Sintoku, Ryosuke, Yajima, Tasuku, Kaneko, Naoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931249/
https://www.ncbi.nlm.nih.gov/pubmed/31875786
http://dx.doi.org/10.1186/s13256-019-2326-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931249/
https://www.ncbi.nlm.nih.gov/pubmed/31875786
http://dx.doi.org/10.1186/s13256-019-2326-y

Ejemplares similares